Skip to content

PolitiKit

Lobbying by Takeda Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Takeda Canada Inc.

Meetings this Parliament
6
With MPs
3
Since Nov 2021
6
Active registrations
1

Most recent reported meeting: Jun 9, 2026.

Registrations in effect

In-house (corporation) In effect since May 4, 2026

Filed by Alan Walshe, General Manager, Takeda Canada Inc.

Lobbyists

  • Alan Walshe · General Manager
  • Denis Laflamme · Senior Manager, Public Affairs and Patient Advocacy Former public office holder

    Formerly Executive Assistant, Minister's Office, Minister of Justice and Attorney General of Canada (1993–1993)

    Formerly Executive Assistant, Minister's Office, Minister of Consumers and Corporate Affairs (1990–1993)

    Formerly Political Assistant, Minister's Office, Solicitor General of Canada (1989–1990)

    Formerly Political Assistant, Minister's Office, Agriculture and Agri-Food Canada (1988–1989)

  • Michelle Hojjati · Senior Manager, Public Affairs and Patient Advocacy
  • Shanna Brisebois · Head of Public Affairs and Patient Advocacy Former public office holder

    Formerly Research Analyst, Liberal Caucus, Liberal Caucus Research Bureau (1999–1999)

Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), CUSMA Secretariat, Canada Economic Development for Quebec Regions, Canada Foundation for Innovation, Canadian Institutes of Health Research (CIHR), Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC), Women and Gender Equality (WAGE)

What they're lobbying on (15)
  • Monitoring and engagement on federal roles in health system planning and preparedness as they relate to blood?related products and plasma?derived medicines used in federally funded programmes and public health responses.
  • Engagement on federal policies and programmes related to the availability, appropriate use, and continuity of supply of plasma?derived therapies, including immunoglobulins, for patients with immune?mediated and rare conditions.
  • Health Canada regulatory modernisation initiatives, including regulatory innovation, flexibility, predictability, and alignment with international approaches.
  • Innovation, Science and Economic Development Canada initiatives and programmes supporting life sciences research, development, and advanced therapies conducted in Canada.
  • Federally funded public drug plans, including programmes for Indigenous Peoples, veterans, and federal plan beneficiaries, with respect to reimbursement of therapeutic products.
  • Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada.
  • Monitoring and engagement on legislation, regulations, and policies related to national pharmacare, including implementation of relevant federal Acts.
  • Monitoring and engagement on the Government of Canada’s National Strategy for Rare Diseases, including related policy frameworks and implementation considerations.
  • Health Canada policies and guidance related to the prevention, monitoring, and management of drug shortages.
  • Regulatory frameworks related to the Patented Medicines (Notice of Compliance) Regulations as they apply to the protection of intellectual property for innovative medicines.
  • Pharmaceutical pricing policy considerations within the mandate of the Patented Medicine Prices Review Board (PMPRB), including regulatory amendments and associated guidance.
  • Engagement on federal policies and frameworks that support improved coordination across jurisdictions to facilitate timely patient access following Health Canada approval.
  • Canada’s Drug Agency policy frameworks and processes related to reimbursement recommendations, including decision?making approaches and timelines.
  • Policies and programmes related to Canada’s Biomanufacturing and Life Sciences Strategy, including support for research, innovation, and manufacturing capability in Canada.
  • Engagement on federal budget priorities and updates affecting the biopharmaceutical sector, including implications for patient access to innovative medicines, vaccines, and therapies.

Registration 964574-385788-2. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by Alan Walshe · In-house (corporation)

    • Kaili Levesque · Associate Deputy Minister, Fisheries and Oceans Canada (DFO)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 6 more
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health, Health Canada (HC)
    • Linsey Hollett · ADM, Health Canada (HC)
    Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada.

    Official report

  • Reported by Alan Walshe · In-house (corporation)

    • Anie Perrault · Chairperson, Patented Medicine Prices Review Board (PMPRB)
    Pharmaceutical pricing policy considerations within the mandate of the Patented Medicine Prices Review Board (PMPRB), including regulatory amendments and associated guidance. Read more

    Official report

  • Reported by Alan Walshe · In-house (corporation)

    • Arianne Reza · Deputy Minister, Public Services and Procurement Canada (PSPC)
    • Joelle Paquette · Acting Associate Deputy Minister, Public Health Agency of Canada (PHAC)
    Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada.

    Official report

  • Reported by Alan Walshe · In-house (corporation)

    Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada.

    Official report

  • Reported by Alan Walshe · In-house (corporation)

    Engagement on federal policies and programmes related to the availability, appropriate use, and continuity of supply of plasma?derived therapies, including immunoglobulins, for patients with immune?mediated and rare conditions. Read more

    Official report

  • Reported by Alan Walshe · In-house (corporation)

    • Maggie Chi · Member of Parliament
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 7 more
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health, Health Canada (HC)
    Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada. Read more

    Pharmaceutical pricing policy considerations within the mandate of the Patented Medicine Prices Review Board (PMPRB), including regulatory amendments and associated guidance.

    Canada’s Drug Agency policy frameworks and processes related to reimbursement recommendations, including decision?making approaches and timelines.

    Engagement on federal policies and frameworks that support improved coordination across jurisdictions to facilitate timely patient access following Health Canada approval.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.